Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

N STATEMENTS OF OPERATIONS (Unaudited) Three months ended March 31, Year ended March 31, 2009 2008 2009 2008 Revenue: Product revenue $2,557,655 $3,136,577 $14,528,916 $18,587,376 Royalty and other revenue 2,036,100 164,200 14,832,605 708,905 Total revenue 4,593,755 3,300,777 29,361,521 19,296,281 Operating expenses: Cost of product revenue 1,341,874 1,303,054 5,685,577 6,160,245 Cost of royalty and other revenue 269,745 - 1,091,297 - Research and development 4,644,799 2,357,696 12,771,573 7,240,812 Selling, general and administrative 1,552,871 3,504,362 5,933,090 10,173,400 Net gain from litigation settlement - - - (40,170,000) Total operating expenses 7,809,289 7,165,112 25,481,537 (16,595,543) Income (loss) from operations (3,215,534) (3,864,335) 3,879,984 35,891,824 Investment income 374,816 668,480 1,895,706 2,051,258 Interest expense (676) (1,744) (2,963) (9,097) Income (loss) before income taxes (2,841,394) (3,197,599) 5,772,727 37,933,985 Income tax (benefit) provision (148,156) - 26,699 827,471 Net income (loss) $(2,693,238) $(3,197,599) $5,746,028 $37,106,514 Earnings (loss) per share: Basic $(0.09) $(0.10) $0.19 $1.20 Diluted $(0.09) $(0.10) $0.18 $1.18 Weighted average shares outstanding: Basic 30,697,818 31,064,4
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... the United States have modified a strain of bacteria ... published in Biotechnology and Bioengineering, reveals how ... improvement, a positive development for the biofuel industry. ... bacterium noted for its bio-ethanol producing potential. However, the ...
... 2010 ACCESS PHARMACEUTICALS, INC. ... leveraging its proprietary drug-delivery platforms to develop treatments in areas ... definitive agreements with existing and new accredited investors to sell, ... million shares of its common stock at a price of ...
... NEW YORK, Dec. 10, 2010 Pfizer Inc. (NYSE: ... interest of patient safety, it is voluntarily withdrawing Thelin® ... in regions where it is approved (the European Union, ... studies of Thelin worldwide. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering 2Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering 3Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... crops places huge demands on water resources around ... is a major contributor to the nation,s economy, ... the agricultural sector. The excessive use of irrigation ... Mediterranean countries, where rising demand has deteriorated groundwater ...
... agricultural land could produce enough biomass to meet renewable ... environment, according to research led by Professor Gail Taylor ... by the UK Energy Research Centre (UKERC), is a ... the potential of planting short rotation coppice (poplar and ...
... will not only teach us more about the way neurons ... diagnostics and therapies for neurological diseases such as Parkinson,s," says ... take a major toll on society. More than 8% of ... cent suffers from a mental disturbance and the number of ...
Cached Biology News:Research on satellite imagery aims to advance sustainable agriculture 2Short rotation energy crops could help meet UK's renewable energy targets 2Skywalker ensures optimal communication between neurons 2
... uses the Adept CE 4100 high pressure dual ... detector for added flexibility and utra low drift. ... to a photodiode array detection and provides superior ... required for method development and for monitoring to ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,448-8) or contact ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
Biology Products: